In the SOPHIA (47) trial, MGAH22 plus chemotherapy had a satisfactory safety profile and showed a significant improved PFS compared to trastuzumab plus chemotherapy in patients with HER2+ advanced breast cancer pre-treated with 2 or more anti-HER2 therapies. Here, ERBB2 is linked to breast carcinoma.